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Are we overusing IVF?
The indications for IVF have expanded from tubal disorders to many causes of subfertility, including
unexplained. But with limited evidence underpinning its extended remit Esme Kamphuis and
colleagues explain how the risks could outweigh the benefits
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Since the birth of the first baby by in vitro fertilisation (IVF) in
1978, the technique has earned its reputation as a major medical
breakthrough of the 20th century. IVFwas developed for women
with tubal disease,1 but its indications soon began to grow. In
the 1990s intracytoplasmic sperm injection was developed to
treat couples in which the man has poor semen quality,2 which
like tubal infertility prevents sperm from coming into close
proximity with an egg. In recent years, however, IVF has been
applied to other types of subfertility such as mild male
subfertility, endometriosis, and unexplained subfertility. The
birth of many healthy children has enhanced provider and patient
confidence in the safety of IVF. But does applying IVF to wider
forms of infertility result in overtreatment of couples who had
a reasonable chance of conceiving naturally? Is it equally
effective in these conditions? And, as more is understood about
the adverse health outcomes in IVF children can the risks of
IVF be justified for these more liberal applications?
Rising rates of IVF
One million babies were born in the first 25 years of IVF
between 1978 and 2003. It took only two more years for the
tally to reach two million in 2005, with over five million
estimated to have been born by the end of 2013.3 In developed
countries with public health systems 2-3% of the births each
year are through IVF, rising as high as 5% in Denmark and
Belgium.4 This is despite the fact that an observational study
showed that 95% of 350 couples planning a first pregnancy
conceive within 24 months.5
The reasons for the rise in IVF are complex. Women may plan
to have children later and some are choosing to freeze their
eggs.6 A lack of confidence, among both subfertile couples and
their doctors, that conception will eventually occur naturally
can lead to access to IVF within two to three years of trying to
conceive, and the lure of new technology and access to more
patient friendly IVF programmes make it more appealing.7
Evidence has also undermined alternatives to IVF such as
clomifene citrate.8 Another factor is that procedures are
increasingly performed in private health systems, where the
focus on commercial returns has resulted in less academic
oversight of who receives treatment and when.9 Amid this the
indications for IVF have been expanded to include mild male
subfertility, the effect of ageing on ovarian function, and
unexplained subfertility where no absolute barrier to conception
can be proved (table 1⇓). And it is in these groups, that use of
IVF is expanding the most.
In the United States, the number of IVF cycles offered annually
increased from 90 000 in 2000 to 150 000 in 2010, but the
proportion with tubal problems as an indication fell from 25%
to 16%.10 In the UK the proportion of IVF cycles for tubal
problems fell from 19% to 12% between 2000 and 2011,
although the number of cycles remained at around 7000 (table
1⇓).11 The figures for unexplained subfertility tripled from 6204
to 19 552 cycles. Similar shifts have been reported in the
Netherlands.12
IVF and unexplained infertility
The value of IVF for tubal blockage and severe male factor
infertility, where a live birth rate of 20-30% per cycle offers the
only chance of conception, is not in dispute. However, the
evidence for newer indications such as unexplained subfertility
is less clear. Unexplained subfertility accounts for 25% to 30%
of all couples presenting for IVF, many of whom will conceive
before treatment.12 13 14 In a cohort of 500 Dutch subfertile
couples with on average almost two years of unexplained
subfertility, 60% conceived naturally after the initial assessment
in the fertility clinic.15 Other observational studies have
confirmed natural conceptions in couples with subfertility for
two to three years.16 17
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ACochrane review comparing IVFwith expectant management
in women without tubal problems identified one trial of 51
women with unexplained infertility who had been trying to
conceive for an average of four years.18 19 The trial reported live
birth rates of 29% in women randomised to one cycle of IVF
versus 1% in the expectant management group. Although this
may seem like a success for IVF, the women in this trial had
been trying to conceive for four years, which is much longer
than is current practice in many countries. A randomised clinical
trial comparing intrauterine insemination and ovarian
hyperstimulation with expectant management in couples who
had an average of two years’ unexplained subfertility found a
pregnancy rate of 25% after six months and 75% after three
years in both groups.17 It seems that a short delay in treatment
does not affect ovarian reserve in such a way that more couples
will end up childless.
Another randomised trial (FASTT) in the US of alternative
strategies in unexplained infertility showed that limiting the
number of cycles of intrauterine insemination with ovarian
hyperstimulation treatment in favour of early access to IVF
reduced the time to pregnancy as well as costs, but it did not
alter the 75% pregnancy rates in both randomised arms at 24
months.20 Evidence from the Netherlands suggests that couples
with a clinical profile similar to those in the FASTT trial would
be expected to have natural conception rates of over 50%.17
It is not just a question of whether to intervene in unexplained
subfertility, but when. Economic modelling studies indicate
that, in younger women with no obvious cause of infertility,
IVF is not cost effective within three years of trying to
conceive.21 However, experimental and observational IVF
research often does not mention how long couples have been
trying to conceive. Forty five of the 71 (63%) randomised trials
of IVF in 2009 and 2010 did not state length of infertility.
National fertility registries in Sweden, Australia, Belgium, New
Zealand, Canada, and the United States also do not collect data
on duration of infertility.
In the UK the National Institute for Health and Care Excellence
changed its recommendation regarding the timing of access to
IVF in couples with unexplained infertility where the woman
is younger than 40 from three to two years.22 However, it did
not provide any references to justify the threshold.
Emerging risks of IVF
Extended use of IVF also increases the risk of harm. Multiple
pregnancies are associated with maternal and perinatal
complications such as gestational diabetes, fetal growth
restriction, and pre-eclampsia as well as premature birth.23 24
And even singletons born through IVF have been shown to have
worse outcomes than those conceived naturally (table 2⇓).25-28
Although some countries have mitigated the risk of multiple
births by requiring single embryo transfer, multiple transfer is
still common in many parts of the world, including the United
States and Asia, where multiple birth rates are 20% to 30%.29
Furthermore, studies suggest that single embryo transfer, which
involves extended embryo culture and transfer of a blastocyst,
is associated with a 50-70% additional risk of preterm birth and
congenital malformations.30-32
Concern has also been raised about the long term health of
children born through IVF. Otherwise healthy children
conceived by IVF may have higher blood pressure, adiposity,
glucose levels, and more generalised vascular dysfunction than
children conceived naturally (table 2⇓). These effects seem to
be related to the IVF procedure itself rather than to underlying
subfertility.33-36 Animal studies have shown epigenetic and
developmental abnormalities after assisted reproduction, which
give further cause for reflection.37 Until these concerns are
resolved, there should be caution about using IVF in couples
when the benefit is uncertain or the chances of natural
conception are still reasonable.
Need to question IVF
A lack of will to question the perceived success of IVF is
preventing progress. Currently funding bodies seem to have
limited interest in funding long term studies on safety. IVF has
evolved in many parts of the world as a profit generating
industry that values the money brought in by immediate gains
of pregnancy and live birth over long term considerations about
the health of the mothers and children. This is true not only for
private clinics but also for academic institutions, which also
benefit economically from the number of couples they recruit
for fertility treatment. Neither the American Society for
Reproductive Medicine nor the European Society of Human
Reproduction and Embryology has guidelines on use of IVF.
Given the rapid increase in uptake of IVF across the world, it
is time to reconnect the drive to “regulate practice” with a drive
to generate knowledge on best practice and long term safety.
IVF has allowed many infertile couples to have a family. Its
early pioneers persevered in opposition to scientific, societal,
and religious dogma. Similar determination is needed in attempts
to evaluate the extension of IVF to new indications. Patients
and researchers are understandably reluctant to include a “no
intervention” arm in randomised clinical trials of IVF, but
without these there is a risk that the balance of benefit and harm
may be disrupted. The paucity of high quality evidence on who
should have IVF and when should be addressed. Trials on
effectiveness of new indications and long term follow-up to
determine the safety of IVF are needed to inform couples.
As a society we face a choice. We can continue to offer early,
non-evidence based access to IVF to couples with fertility
problems or follow a more challenging path to prove
interventions are effective and safe and to optimise the IVF
procedure.We owe it to all subfertile couples and their potential
children to use IVF judiciously and to ensure that we are first
doing no harm.
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Tables
Table 1| Table 1 Evidence of effectiveness of IVF treatment for different types of infertility and change in indications between 2000 and
2011 in the United Kingdom11
No (%) of IVF cycles
Evidence of effectivenessReason for fertility problem
2011
(n=60 473)
2000
(n=35 450)
7 470 (12%)*6771 (19)*Effective: no chance of conception without medical assistance1 2Two sided tubal pathology
19 643 (33%)†9777 (28)†Severe male infertility
††Obstructive male infertility
6%7%Anovulation
19 552 (32)6204 (18)IVF treatment effective in subfertility>4 years; no more effective than less invasive
alternatives in subfertility <2.5 years; effectiveness unknown for subfertility 2.5-4
years18
Unexplained subfertility
**One sided tubal pathology
††Mild male subfertility
2 550 (4)886 (3)Endometriosis
NANANo comparative effectiveness data availablePoor ovarian reserve
NANAAdvanced maternal age
11 252 (12)12 691 (25)Other or mixed factors
* One sided and double sided tubal pathology were reported together.
† Severe male infertility, obstructive male infertility, and mild male subfertility reported together.
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Table 2| Potential harms of IVF in singleton pregnancies compared with natural conception
Odds ratio (95% CI)
Perinatal outcomes
1.5 (1.5 to 1.6)Preterm birth (<37 weeks)26 35
1.7 (1.5 to 1.9)Very preterm birth (<32 weeks)26 35
1.7 (1.6 to 1.8)Low birth weight (<2500 g)26 35
1.9 (1.7 to 2.2)Very low birth weight (<1500g)26
1.9 (1.5 to 2.4)Perinatal mortality26
1.4 (1.3 to 1.5)Small gestational age26
1.7 (1.3 to 2.1)Congenital malformations26 36
Long term outcomes
2.8 (1.3 to 16)Cerebral palsy36
IncreaseGeneralised vascular dysfunction33
61/109 v 59/105Diastolic/systolic blood pressure (mm Hg)34
Increase or no changeFat deposition35
Increase or no changeFasting glucose35
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